Bd innovation profiled in cover story of 'science' demonstrates landmark advancement in flow cytometry technology

Franklin lakes, n.j., jan. 20, 2022 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced that a study conducted in collaboration with the european molecular biology laboratory (embl) and published as the cover story of the january 21 st  issue of the journal, science, profiles a new bd innovation in flow cytometry that adds fluorescence imaging and image-based decisioning to sort individual cells at exceptionally high speed, based on the visual details of each cell and not solely on the type or quantity of biomarkers that are present.
BDX Ratings Summary
BDX Quant Ranking